Covid 19 Research using Clinical Trials (Home Page)
Lopinavir/Ritonavir 200 MG-50 MG Oral TabletWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
|
Name (Synonyms) |
Correlation |
drug2993 | samling of oropharynx and nasopharynx Wiki | 1.00 |
drug238 | Atorvastatin 20 Mg Oral Tablet Wiki | 1.00 |
drug2468 | Telmisartan 40Mg Oral Tablet Wiki | 1.00 |
Correlated MeSH Terms (2)
|
Name (Synonyms) |
Correlation |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
In January 2020, the new SARS-CoV-2 coronavirus was identified in China. The disease caused
by this coronavirus was named COVID-19 by the World Health Organization (WHO). Since March
11, 2020, the WHO has described the global situation of COVID-19 as a pandemic. In Côte
d'Ivoire, as in other African countries, the number of cases is increasing exponentially.
Coronaviruses are a family of viruses that cause illnesses ranging from the common cold to
more severe pathologies. COVID-19 can result in fever or a feeling of fever (chills,
hot-cold), cough, headache, aches and pains, unusual tiredness, sudden loss of smell, total
disappearance of taste, or diarrhea. In severe forms, respiratory difficulties can lead to
hospitalization in intensive care or even death.
Numerous studies are currently being conducted around the world to seek effective treatment,
but few of them have started specifically in Africa. Moreover, most of these studies are
using a single drug to control the infection, whether these are repositioned drugs, i.e.
already being used for other diseases, or other newer drugs.
Currently in Côte d'Ivoire, the preferred treatment for COVID-19 is an antiviral:
lopinavir/ritonavir (LPV/r), usually directed against the Human Immunodeficiency Virus (HIV).
Since the number of viruses (viral load) is high in the respiratory tract during COVID-19
infection, we propose in INTENSE-COV (ICOV) clinical trial to study whether the combination
of two drugs is more effective than taking a single drug on reducing the viral load in the
respiratory tract but also on reducing inflammation.
These drugs include the LPV/r already in use in Côte d'Ivoire as well as an antihypertensive
drug - telmisartan, and a drug that lowers blood cholesterol - atorvastatin. All three have
been known for a long time and have been shown to be effective against other viruses. In
addition, they are generic, inexpensive and readily available in all countries.
The objectives of the ICOV study are therefore to improve viral eradication from the
patient's body and respiratory tract, to reduce inflammation, to improve more rapidly the
patient's state of health and to reduce the risk of transmission of the virus to others.
To participate in ICOV, patients must be over 18 years of age, have a COVID-19 infection
confirmed by a specific test, have clinical manifestations of the infection, and have signed
an informed consent. They will then be randomized into 3 treatment groups to ensure the
robustness of the study results. The reference group will be treated with LPV/r, according to
current recommendations in Côte d'Ivoire. The other 2 groups will be treated with LPV/r +
telmisartan and LPV/r + atorvastatin respectively. The treatment will last 10 days and
patients will be followed for a total of 28 days.
NCT04466241 COVID-19 COVID-19 Drug Treatment Severe Acute Respiratory Syndrome Coronavirus 2 Drug: Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet Drug: Telmisartan 40Mg Oral Tablet Drug: Atorvastatin 20 Mg Oral Tablet
Primary Outcomes
Measure: Proportion of patients with undetectable nasopharyngeal swab SARS-CoV-2 PCR and C-reactive protein (CRP) < 27 mg/L at Day 11 Time: Day 11
Secondary Outcomes
Measure: Proportion of patients with clinical improvement on the 7-point ordinal scale at Day 11 and Day 28 Time: Day 11 and Day 28
Measure: Kinetics of SARS-CoV-2 viral load Time: Up to Day 28
Measure: Death rate at Day 11 and Day 28 Time: Day 11 and Day 28
Measure: All causes of death and Acute respiratory distress syndrome (ARDS) at Day 28 Time: Day 28
Measure: Time to hospital discharge Time: Up to Day 28
Measure: Duration of oxygen supplementation Time: Up to Day 28
Measure: Prevalence of grade III or IV adverse events Time: Up to Day 28
Measure: Residual concentration of lopinavir, telmisartan and atorvastatin Time: Up to Day 28
Measure: Evolution of inflammatory and immunological markers (CRP, fibrinogen, ferritin, d-dimer, dosing of IgG, IgA, IgM; TCD4, CD8, B lymphocytes, NK lymphocytes; naïve/memory T lymphocytes) Time: Up to Day 28
Measure: Evolution of endothelial activation markers (VEGF and soluble VEGF receptor,VE-cadherin, PECAM/CD31, CD42 and angiopoietin-2) Time: Up to Day 28
Measure: Proportion of patients with good results according to HIV status Time: Up to Day 28
Measure: Number of contact cases infected by COVID-19 at Day 28 Time: Day 28
No related HPO nodes (Using clinical trials)